恒瑞医药(600276.SH)：HRS-6257片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of HRS-6257 tablets, which are intended for the treatment of acute and chronic pain [1] Group 1 - The clinical trial approval notification for HRS-6257 tablets was issued by the National Medical Products Administration [1] - The clinical trials for HRS-6257 tablets are set to commence in the near future [1] - HRS-6257 tablets are aimed at addressing the treatment needs for both acute and chronic pain [1]